Glycomedicine is an emerging interdisciplinary field that investigates how glycans—complex carbohydrates attached to proteins, lipids, and nucleic acids—regulate biological processes and shape health and disease. While the classical central dogma of molecular biology describes the flow of information from DNA to RNA to protein, this linear framework alone cannot fully explain the regulatory complexity of living systems. The concept of the paracentral dogma has recently been proposed to address this gap, emphasizing parallel, non-template–driven information pathways—most notably glycan-based sugar codes—that operate alongside and in support of the central dogma.
Unlike genes and proteins, glycans are not directly encoded by a nucleic acid template. Instead, they are synthesized through coordinated enzymatic networks in the endoplasmic reticulum and Golgi apparatus. This biosynthetic process generates remarkable structural diversity, enabling glycans to function as a molecular language, often referred to as the sugar code. Within the paracentral dogma framework, this sugar code acts as a contextual regulator, modulating how genetic and proteomic information is expressed rather than replacing it. In this sense, glycans refine, diversify, and localize biological signals downstream of gene expression.
The biological relevance of the paracentral dogma becomes evident in immunity, development, and disease. Cell-surface glycans mediate cell–cell recognition, immune tolerance, and host–pathogen interactions, while intracellular glycosylation events such as O-GlcNAcylation link nutrient availability and metabolic status to transcriptional regulation and stress responses. These mechanisms illustrate how glycan-mediated regulation forms a parallel informational layer that integrates environmental and physiological inputs with the core genetic program.
Clinically, glycomedicine translates the paracentral dogma into practical applications. Glycoconjugate vaccines exploit pathogen-specific sugar signatures to induce protective immunity, while disease-associated changes in glycosylation patterns serve as sensitive biomarkers for cancer, inflammatory disorders, and metabolic disease. Because glycan profiles reflect the combined influence of genes, metabolism, and environment, they provide a systems-level readout that complements genomic and proteomic data.
In summary, the paracentral dogma reframes molecular biology by recognizing glycans as active information carriers that operate in parallel with DNA, RNA, and proteins. Glycomedicine, grounded in this expanded conceptual framework, offers powerful opportunities for precision diagnostics, preventive strategies, and targeted therapies. By decoding sugar codes within the paracentral dogma, biomedical research moves closer to a holistic understanding of biological regulation and personalized health.
Professor of global health and glycomics, Edith Cowan University (ECU), Western Australia and overseas adjunct professor, Shantou University Medical College, China.
Prior to joining ECU, Professor Wang was Vice Director-Research of Peking University-Hong Kong University of Sciences & Technology Medical Centre in Shenzhen, Vice Dean of School of Life Science, University of Chinese Academy of Sciences, and Dean of School of Public Health and Family Medicine, Capital Medical University, Beijing, China and Professor, Public Health, Edith Cowan University, Australia.
He has published over 300 scientific papers on global health, glycomics, and predictive, preventiveand personalized medicine.
Professor Wang holds the degrees of Doctor of Medicine from China Medical University, and Doctor of Philosophy from Oita Medical University, Japan. In 2005 he was elected as a Fellow, Faculty of Public Health, Royal College of Physicians (FFPH), and in 2016, as a Fellow, Royal Society of Biology (FRSB), and in 2017 a Fellow, Royal Society of Medicine (FRSM) of the United Kingdom.